The QualityStocks Daily Wednesday, July 31st, 2024

Today's Top 3 Investment Newsletters

Premium Stock Alerts(NUZE) $5.9800 +61.62%

MarketClub Analysis(LSH) $3.8000 +60.34%

QualityStocks(BEDU) $2.2000 +33.33%

The QualityStocks Daily Stock List

Bright Scholar Education Holdings (BEDU)

The Online Investor, StreetInsider, MarketBeat, Trades Of The Day, Trading Concepts, TradersPro, StockMarketWatch, QualityStocks, InvestorPlace, FreeRealTime and Daily Trade Alert reported earlier on Bright Scholar Education Holdings (BEDU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bright Scholar Education Holdings Ltd (NYSE: BEDU) (FRA: BSK) is an education service provider that is focused on operating and providing K-12 schools and complementary education services.

The firm has its headquarters in Foshan, China and was incorporated in 1994, on February 18th by Mei Ring Yang. It serves consumers internationally, with a focus on the People’s Republic of China.

The company is dedicated to offering quality international education to students in China and equipping them with the crucial academic foundation and skills needed to succeed in the pursuit of higher education overseas. It operates through the Education Technology, Overseas School, Complementary Education Services, Kindergartens, Bilingual Schools and International Schools segments. The company generates the majority of its revenue from the International Schools segment. Geographically, most of its revenue comes from China.

The enterprise provides a broad range of internationally-accredited curriculum in its schools. This is in addition to offering a range of complementary education services, which include after-school programs and international camps, as well as international education consulting services. It also complements its international offerings with government-mandated curriculum for those who wish to pursue higher education in China. As of August 2020, the enterprise operated 8 international schools and 94 schools across twelve provinces in China, with a student capacity of more than 75,000 students.

The firm is focused on achieving its long term strategic initiatives through enhancing the efficiency of its businesses and rebuilding its revenue growth for overseas business. It is also setting up its businesses to capture market opportunities, which will be good for its overall growth.

Bright Scholar Education Holdings (BEDU), closed Wednesday's trading session at $2.2, up 33.3333%, on 79,129 volume. The average volume for the last 3 months is 1.011M and the stock's 52-week low/high is $0.8121/$3.23.

Bone Biologics (BBLG)

QualityStocks, FreeRealTime, Tim Bohen, The Stock Dork, StockEarnings and MarketClub Analysis reported earlier on Bone Biologics (BBLG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bone Biologics Corp. (NASDAQ: BBLG) is a medical device firm that is centered on bone regeneration in spinal fusion, through the use of recombinant human proteins.

The firm has its headquarters in Burlington, Massachusetts and was incorporated in 2004 by Benjamin Wu, Chia Soo and Eric Kang Ting. It serves consumers in the United States.

The company’s aim is to improve clinical outcomes and decrease total healthcare costs linked to spinal fusion. It is party to a license agreement with UCLA Technology Development Group, which entails the development and commercialization of its NELL-1 product that has been developed for spinal-fusion applications.

The enterprise’s pipeline comprises of its combination product known as NELL-1/DBX, which is an osteo-stimulative recombinant protein which offers target control over bone regeneration without causing inflammation or leading to poor bone formation. This osteopromotive growth factor has shown that it can effectively increase the quality and quantity of bone across large and small animal models. It is also developing a device indicated for spinal fusion procedures in patients with degenerative disc disease at a single level from L4-21, known as the NELL-1/DBX Fusion Device. The enterprise’s platform technology has applications in delivering better outcomes in the specialties of sports, interventional radiology, neurosurgery, plastic reconstruction, general orthopedic, orthopedic and spinal medicine.

With the osteoporosis drugs market set to grow exponentially during this decade, the firm is well positioned to grow significantly as it addresses unmet patient needs by offering technologies that improve bone repair and regeneration in areas where present options offer sub-optimal outcomes.

Bone Biologics (BBLG), closed Wednesday's trading session at $2.16, up 22.7273%, on 4,668,145 volume. The average volume for the last 3 months is 84,814 and the stock's 52-week low/high is $1.00/$11.76.

GD Culture (GDC)

INO Market Report, QualityStocks, Prism MarketView, MarketClub Analysis and bullseyeoptiontrading reported earlier on GD Culture (GDC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GD Culture Group Limited (NASDAQ: GDC) is a holding firm that operates through its primary business conduit, AI Catalysis Corp.

The firm has its headquarters in Nevada and was incorporated in 2018, on February 6th. Prior to its name change in January 2023, the firm was known as Code Chain New Continent Ltd. It operates as part of the electronic gaming and multimedia industry, under the communication services sector. The firm serves consumers around the globe.

The company’s main businesses include AI-driven digital human technology; Live-streaming e-commerce; and Live streaming interactive games. Under its AI business division, it is focused on providing technology application services of digital human creation and customization for social media influencers or SMBs (Small and Medium-sized Businesses) in the consumer industry to help the clients optimize their online marketing and advertising. Under the e-commerce business, its focus is on capturing TikTok's popular trend by offering carefully selected product choices with smooth delivery, aiming to redefine the online shopping experience. It has formulated a dual strategy employing both short video and live streaming to afford online shoppers a more convenient and interactive shopping experience. On the other hand, the interactive game division is focused on diversifying its game offerings and the anchor personalities for TikTok users.

The firm, through its AI Catalysis subsidiary, announced recently that its portfolio company, DigiTrax Entertainment Inc. had unveiled a new AI Music Training Model License offered in its patented AI platform KR38R LAB’s Artist and Label Services. This move unlocks innovative AI-driven creative possibilities and may positively influence investments into the firm.

GD Culture (GDC), closed Wednesday's trading session at $1.41, up 10.1562%, on 91,424 volume. The average volume for the last 3 months is 152,327 and the stock's 52-week low/high is $0.585175/$5.34.

Zynex, Inc. (ZYXI)

TaglichBrothers, QualityStocks, MarketBeat, MarketClub Analysis, Trades Of The Day, SmarTrend Newsletters, Daily Trade Alert, The Wealth Report, InvestorPlace, BUYINS.NET, Zacks, FeedBlitz, SeeThruEquity Research, SmallCapVoice, StockMarketWatch, FNNO Newsletters, The Street, TradersPro, Daily Markets and Schaeffer's reported earlier on Zynex, Inc. (ZYXI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Zynex, Inc. is a medical technology company listed on the OTCQB. It specializes in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neuro diagnostics, cardiac and blood volume monitoring.  In addition, the Company is developing a new blood volume monitor (non-invasive Blood Volume Monitor, CM-1500) for use in hospitals and surgery centers. Zynex was founded by Mr. Thomas Sandgaard, the Company’s current Chief Executive Officer and Chairman.  Zynex has its corporate office in Englewood, Colorado.

The Company’s product lines are completely developed, Food and Drug Administration (FDA)-cleared, and commercially sold internationally. Zynex engineers, manufactures, markets, and sells its own design of medical devices in three subsidiaries.

Zynex Medical is a provider of electrotherapy products for home use.  Zynex Monitoring Solutions develops products for cardiac monitoring for use in hospitals. Zynex NeuroDiagnostics develops devices for EMG and EEG diagnostic purposes in the neurology clinic markets.

The Company’s belief is that its non-invasive Blood Volume Monitor, CM-1500, will be the first device to provide an indication of fluid balance and blood loss in the operating room or potential post-surgical internal bleeding in recovery. Zynex markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation.

Furthermore, Zynex markets and sells its proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. The design of the NeuroMove™ device is to assist stroke survivors in regaining movement using the brain's ability to rewire itself, also known as "neuro-plasticity".

Zynex, Inc. (ZYXI), closed Wednesday's trading session at $9, up 9.4891%, on 355,845 volume. The average volume for the last 3 months is 1.257M and the stock's 52-week low/high is $6.88/$13.77.

Femto Technologies (BCAN)

StockWireNews, Small Cap Firm, QualityStocks, Fierce Analyst, Broad Street, StockStreetWire, OTC Stock Review, MarketClub Analysis, FreeRealTime, Small Caps, INO Market Report and CFN Media Group reported earlier on Femto Technologies (BCAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Femto Technologies Inc. (NASDAQ: BCAN) is a company focused on the development and manufacture of women’s wellness devices and services.

The firm has its headquarters in Kiryat Motzkin, Israel and was incorporated in 2021, on March 29th. Prior to its name change in July 2024, the firm was known as BYND Cannasoft Enterprises Inc. It operates as part of the software-application industry, under the technology sector. The firm serves consumers around the globe.

The company pioneers in women's care technology, focused on advancing women's wellness and lifestyle, leveraging its Smart Release Technology and core ability to innovate data-driven products to focus on the development of smart products in the sectors of intimacy, sports, hair, and cosmetics.

The enterprise owns and markets Benefit CRM, a customer relationship management (CRM) software product enabling small and medium-sized businesses to optimize their day-to-day business activities such as sales management, personnel management, marketing, call center activities, and asset management. It owns the intellectual property for the EZ-G device. This therapeutic device uses proprietary software to regulate the flow of low concentrations of cannabidiol oil, hemp seed oil, and other natural oils into the soft tissues of the female reproductive system to potentially treat a variety of women's health issues.

The firm’s recent name change highlights its strategic focus and growth abilities. It is positioned at the forefront of technological innovation, as it works to enhance women's health and wellbeing through cutting-edge technology. The firm’s success will not only benefit women globally but also encourage additional investments into the firm, which will positively influence its overall growth.

Femto Technologies (BCAN), closed Wednesday's trading session at $0.6147, up 1.5697%, on 561,036 volume. The average volume for the last 3 months is 79,266 and the stock's 52-week low/high is $0.5428/$292.60.

Bit Mining Ltd. (BTCM)

QualityStocks, MarketClub Analysis, StockEarnings, Schaeffer's, CryptoCurrencyWire, Wall St. Warrior, The Stock Dork, StocksEarning, smartmoneytrading, MarketBeat, INO Market Report, FreeRealTime and 247 Market News reported earlier on Bit Mining Ltd. (BTCM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Former President Donald Trump is working to solidify his presidential bid by appealing to the crypto industry and attracting campaign donations. However, a new dynamic has emerged with the rise of Kamala Harris. Trump’s presence at the Bitcoin (BTC) 2024 conference in Nashville indicates that a second term for Trump could bring favorable digital asset policies. Meanwhile, major crypto companies and investors are gearing up to spend significant sums to sway this year’s elections.

Industry insiders anticipate Trump will use his speech to advocate for increased BTC mining in the United States and to oppose the Fed’s potential creation of a digital currency — both positions that align with the GOP’s recently released platform. Some cryptocurrency backers anticipate that Trump will go one step further and accept a proposal to create a strategic reserve for Bitcoin held by the government.

However, Harris’s growing influence poses a potential challenge. Trump has positioned his procrypto stance as a counter to President Joe Biden, whose administration has been tough on the industry. With the campaign landscape shifting, Democrats who support crypto are optimistic that Harris could adopt a more lenient approach. Although she hasn’t explicitly addressed digital asset regulation as vice president, her age and background in tech-savvy California offer reasons for optimism among crypto enthusiasts.

It may be premature to speculate about Harris’s position on cryptocurrencies, as she is likely to align with the record of the Biden administration. Before Biden exited the race, his team appeared more open to addressing crypto concerns, as evidenced by senior adviser Anita Dunn’s meetings with industry executives in Washington.

Within the Democratic Party, opinions on cryptocurrency remain divided. This week, prominent crypto-skeptic Senator Elizabeth Warren criticized a bill that Chuck Schumer, the Senate majority leader, expressed interest in advancing. Crypto skeptics are putting pressure on Harris to stick to her principles in the face of a potential change.

Trump’s embrace of cryptocurrency isn’t a sudden development. Since Trump’s departure in 2021, the GOP has been advocating for procrypto policies more and more. However, Trump has significantly benefited from his new support for crypto, with crypto billionaires such as the Winklevoss twins, Ben Horowitz and Marc Andreessen backing Trump. His campaign has also received millions in cryptocurrency donations since it started accepting crypto in May.

Before his address in Nashville, Trump is scheduled to host an $844,600 per person fundraiser that includes a roundtable, a VIP reception and photo opportunities with him. An entry-level ticket that costs $60,000 for an individual or $100,000 for a couple gets you into the reception and a picture with Trump. Trump is anticipated to use his procrypto position against Harris.

Industry actors such as Bit Mining Ltd. (NYSE: BTCM) and the entire crypto industry hope that the campaign period helps to draw attention to the need to formulate regulations that foster innovation and growth in the industry while protecting customers.

Bit Mining Ltd. (BTCM), closed Wednesday's trading session at $2.78, up 0.7246377%, on 56,586 volume. The average volume for the last 3 months is - and the stock's 52-week low/high is $1.79/$6.95.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO)

Green Car Stocks, InvestorPlace, QualityStocks, StocksEarning, Kiplinger Today, Schaeffer's, MarketClub Analysis, StockMarketWatch, TradersPro, GreenCarStocks, StockEarnings, BUYINS.NET, Trades Of The Day, MarketBeat, The Street, TopPennyStockMovers, Zacks, Daily Trade Alert, The Online Investor, Small Cap Firm, SmallCapVoice, VectorVest, Eagle Financial Publications, Cabot Wealth and PoliticsAndMyPortfolio reported earlier on ElectraMeccanica Vehicles Corp. Ltd. (SOLO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Luxury high-performance sports car carmaker Porsche has announced that it is abandoning its electric vehicle targets due to sluggish EV demand. Porsche is the latest in a growing list of established automakers that made ambitious electrification plans but have been forced to scale back amid falling electric vehicle demand and slowed EV uptake. With consumers in most major markets dealing with high interest rates and rising living costs, very few are willing to spend tens of thousands of dollars more for an EV.

Porsche was looking to crack into the luxury EV market with the Porsche Taycan EV, but the German automaker is going back to the drawing board after market demand failed to meet its expectations. The decision to abandon its electric vehicles targets came soon after Porsche warned that the aluminum-parts shortage caused by a flooding incident down the supply chain had impacted its vehicle production line.

As the automotive sector contends with lower-than-predicted electric vehicle demand, Porsche is now ditching its plan to make electric vehicles 80% of its new vehicle sales by 2030. Like many other automakers, Porsche was initially keen on electrifying its vehicle line in record time and pledged to invest considerable resources to achieve this goal. However, Porsche executives now say the carmaker will only pursue electrification based on market demand rather than strict deadlines.

A statement from Porsche said that the electric-vehicle transition would take longer than the company assumed half a decade ago when it set its electrification targets. The company noted that its product strategy would still allow it to sell up to 80% electric vehicles by 2030 if there is enough consumer demand and if electric-vehicle technology advances further. According to a Porsche spokesperson, the automaker is “reflecting the situation” around global e-mobility development rather than cutting its electrification goals.

The global electric-vehicle industry has experienced significant growth over the past decade as climate-change mitigation efforts takes center stage in international politics. Electrifying the world’s road transportation would help to cut greenhouse-gas emissions by nearly 30% and put the world on track to achieving carbon neutrality. As Tesla’s valuation grew by leaps and bounds, established automakers poured vast amounts of money into developing EVs and remained incredibly bullish, despite the high EV prices and insufficient charging infrastructure that hindered EV ownership.

Sluggish electric-vehicle demand in most major markets dealt a major blow to these ambitious electrification plans and left many carmakers with scaled-down strategies that will see them sell internal combustion engine (ICE) cars as well as hybrids and battery electric vehicles (BEVs). Even so, Porsche says it will continue to monitor the EV market and remain flexible so it can react to regulations and consumer requirements in time.

The coming months are likely to reveal how other EV makers such as ElectraMeccanica Vehicles Corp. Ltd. (NASDAQ: SOLO) will adapt to the changing market dynamics in this industry.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO), closed Wednesday's trading session at $0.2122, even for the day. The average volume for the last 3 months is 18.919M and the stock's 52-week low/high is $0.1999/$0.9599.

Microsoft Corp. (MSFT)

The Street, InvestorPlace, Kiplinger Today, The Online Investor, Zacks, Daily Trade Alert, StockMarketWatch, Schaeffer's, StreetInsider, MarketClub Analysis, StreetAuthority Daily, Money Morning, Investopedia, TopStockAnalysts, Trades Of The Day, IT News Daily, InvestorGuide, Market Intelligence Center Alert, internetnews, Early Bird, MarketBeat, PROFIT CONFIDENTIAL, QualityStocks, The Motley Fool, Daily Wealth, Uncommon Wisdom, Top Pros' Top Picks, NetworkNewsWire, internet, Stocks to Buy Now, SeriousTraders, SmallCapRelations, Wealth Insider Alert, Louis Navellier, Daily Market Beat, Flagler Financial Group, Street Insider, ProfitableTrading, Investor Guide, Cabot Wealth, The Wealth Report, Barchart, The Street Report, INO Market Report, CNBC Breaking News, Wyatt Investment Research, StocksEarning, SmarTrend Newsletters, Dividend Opportunities, SiliconValley, Daily Profit, StrategicTechInvestor, MarketWatch, Insider Wealth Alert, Money and Markets, GorillaTrades, Investors Alley, CustomerService, iStockAnalyst, Stansberry Research, TradingAuthority Daily, INO.com Market Report, TipRanks, Trading Markets, The Growth Stock Wire, FreeRealTime, Wealth Daily, Investment U, TheStockAdvisors, WStreet Market Commentary, Marketbeat.com, Investing Daily, Total Wealth, Willy Wizard, Greenbackers, Wall Street Daily, Energy and Capital, AllPennyStocks, TheStockAdvisor, Daily Markets, Money Wealth Matters, Eagle Financial Publications, DividendStocks, Contrarian Outlook, Market Intelligence Center, Trade of the Week, Investiv, Penny Stock Buzz, SmallCap Network, Shah's Insights & Indictments, Dynamic Wealth Report, Darwin Investing Network, FeedBlitz, Trader Prep, Market Authority, Forbes, FNNO Newsletters, Power Profit Trades, The Night Owl, StockEarnings, Investor Update, Wall Street Elite, SmallCapVoice, The Daily Market Alert, Daily Dividends, Short Term Wealth, TradingMarkets, BullDogReporter, Stockhouse, TraderPower, Stock Up Featured, Coattail Investor, Inside Investing Daily, StockTwits, Trading Concepts, Jon Markman’s Pivotal Point, CRWEFinance, The Trading Report, The Best Newsletters, Bourbon and Bayonets, Options Elite, Wall Street Greek, InvestmentHouse, Investment House, Investing Lab, Investing Futures, PennyOmega, InvestorsObserver Team, Super Stock Investor, DrStockPick, The Weekly Options Trader, TheOptionSpecialist, MarketMovingTrends, Traders For Cash Flow, Momentum Traders, ChartAdvisor, 24/7 Trader, MarketArmor.com, Momentum Trades, The Stock Dork, YOLOTraderAlerts, PennyToBuck, SmallCapNetwork, Stocks To Watch, CRWEWallStreet, equities Canada, Agora Financial, The Tycoon Report, Stock Gumshoe, Leeb's Market Forecast, Visual Capitalist, InvestorIntel, Wealthpire Inc., Smartmoneytrading, Early Investing, Untapped Wealth Online and StreetAlerts reported earlier on Microsoft Corp. (MSFT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OpenAI recently announced that it had begun tests on its new search engine, which uses generative artificial intelligence (AI) to produce results. The American artificial intelligence research organization was behind the launch of ChatGPT, the now famous chatbot and virtual assistant launched about two years ago.

The company revealed last week that SearchGPT would be rolled out to a small group of publishers and users before being launched to a wider market. The company plans to incorporate the search features into its chatbot, instead of launching a standalone product.

In its statement, OpenAI explained that its search engine was a temporary prototype that would merge its artificial intelligence models with the ability to search the internet. SearchGPT has been designed to respond conversationally to searches, while offering the latest information based on relevant sources. This new feature positions OpenAI as a direct competitor to major search engines, including Google and Bing, the latter being a product of Microsoft Corp. (NASDAQ: MSFT), which has invested heavily in OpenAI.

In a blogpost, OpenAI explained that finding information online required effort, needing multiple attempts to acquire relevant results. It noted that by improving the conversational capabilities of its models with real-time data from the internet and promoting trusted sources, users could find what they were looking for easier as well as faster.

This comes at a time when OpenAI is fighting legal action over alleged copyright violations.

In the last couple of months, a number of media organizations and news outlets, including the Intercept, the Chicago Tribune and the New York Times, have filed lawsuits against OpenAI. In their suits, the plaintiffs argue that the AI research organization has illegally trained its artificial intelligence models on their published work without offering them compensation or obtaining consent, effectively profiting off of protected material while plagiarizing their work.

OpenAI has refuted these claims, arguing that the services they offer create something new and fall under the doctrine of “fair use.”

These developments come as tech companies continue to integrate generative artificial intelligence into their search engines. Google recently launched AI Overviews, a search feature enabled by artificial intelligence that summarizes information from search results and eliminates the need for users to look through various sites.

While the tech giant announced the feature’s success in its recent earnings call, the offering’s launch was met with criticism from creators and publishers who were concerned that it diverted ad revenue and traffic away from their websites.

Microsoft Corp. (MSFT), closed Wednesday's trading session at $418.35, off by 1.0806%, on 42,891,366 volume. The average volume for the last 3 months is 413,974 and the stock's 52-week low/high is $309.45/$468.35.

Trulieve Cannabis Corp. (TCNNF)

QualityStocks, InvestorPlace, MarketBeat, Wealth Insider Alert, Daily Trade Alert, Cabot Wealth, Top Pros' Top Picks, The Street, Trades Of The Day, Profit Trends, CannabisNewsWire, TradersPro, The Online Investor, StreetInsider and Prism MarketView reported earlier on Trulieve Cannabis Corp. (TCNNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Businesses in the cannabis industry, similar to other businesses, are required to comply with energy and environmental rules established by their respective states. Such rules may include how to adhere to standards on energy efficiency requiring specific lighting or HVAC equipment, or how to dispose of or treat wastewater.

This industry’s huge impact on the environment, particularly the significant use of water and energy, is drawing the attention of regulators. This has prompted some states to enact cannabis-specific environmental regulations in response. States that have taken such action include Illinois, California, New York, Michigan and Massachusetts.

A number of towns and cities have also implemented similar environmental measures, including Boulder, Colorado; Beverly, Massachusetts; and Grand Rapids and Ann Arbor in Michigan.

While these jurisdictions have their own regulations, some common themes have been observed, a good example being the efforts being made to decrease the high use of energy by the marijuana industry.

Below, we look at the ecoregulations of the different jurisdictions in detail.

Illinois

All growers in the state, depending on their size, are required to use variable refrigerant-flow HVAC units; split, ductless HVAC units; or similar energy-efficiency HVAC options. The state has also made it compulsory for growers to have equipment to capture condensate as well as automated watering systems.

It should be noted that the regulations apply only to recreational growers.

California

The state mandates that cultivators use chilled water systems and integrated HVAC systems with on-site heat recovery to reheat dehumidified air.

Vermont and New York

Both states require that during license renewals and applications, companies submit yearly reports showing their use of gas, water and energy.

Oregon and New Jersey

The states require that applicants of cultivation licenses submit waste-management plans as well as water and energy-use plans.

Massachusetts

The state of Massachusetts has implemented a rule similar to that of New Jersey and Oregon. It also directs that the lighting power density of all cultivators not be higher than 36 watts per feet of canopy.

While these regulations look easy enough to implement, Climate Resources Group’s principal Sam Milton says that isn’t the case. Milton explains that these rules are hard to enforce in these jurisdictions, with the exception of Massachusetts, which uses an independent third-party evaluator to ensure that licensees are conforming to environmental regulations. He also highlights the importance of growers being educated on the rebates afforded to them when they purchase energy-efficient equipment. Information and incentives, Milton notes, may be more effective than rules in this case.

This patchwork of environmental laws is just another illustration of the challenges that MSOs such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) have to contend with as they navigate different regulations in each market they are licensed to operate within.

Trulieve Cannabis Corp. (TCNNF), closed Wednesday's trading session at $10.1, off by 0.6882989%, on 269,009 volume. The average volume for the last 3 months is 9.857M and the stock's 52-week low/high is $3.42/$14.50.

QuantumScape Corp. (QS)

StockEarnings, Schaeffer's, InvestorPlace, QualityStocks, StocksEarning, MarketClub Analysis, The Street, MarketBeat, GreenCarStocks, The Online Investor, Cabot Wealth, FreeRealTime, Daily Trade Alert, Top Pros' Top Picks, Atomic Trades, BUYINS.NET, CNBC Breaking News, Premium Stock Alerts, INO Market Report, wyatt research newsletter, 360 Wall Street, Trades Of The Day, Zacks, TipRanks and Green Energy Stocks reported earlier on QuantumScape Corp. (QS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PowerCo, the battery division of Volkswagen Group, and QuantumScape Corp. (NYSE: QS) have inked a partnership that will see the lithium-based, solid-state batteries developed by QuantumScape mass produced by Volkswagen Group’s battery production arm. This strategic collaboration is intended to bolster EV battery safety and performance by quickly bringing to market the novel solid-state batteries.

Through this partnership, QuantumScape agreed to give PowerCo a license to manufacture EV batteries based on QuantumScape’s cutting-edge battery technology. PowerCo has been permitted to make approximately 40GWh of these battery cells each year, and the company will be at liberty to ramp up its production to twice this volume if and when the need arises. It should be noted that the agreement QuantumScape reached with PowerCo doesn’t forestall the battery developer from entering similar arrangements with other entities.

This new battery technology largely hinges on the ceramic separator, which is a game-changer due to its ability to revolutionize power delivery, battery safety and energy density. The technology is proprietary.

As a result of the agreement, Volkswagen will have an opportunity to install the novel batteries in its EVs. The impact of this step is that electric vehicles will be taken into a whole new direction, and motorists will be able to enjoy unprecedented quick charging and superior battery performance. PowerCo CEO Frank Blome expressed the company’s excitement at taking this battery to mass production so that customers can access these sustainable and superior batteries.

PowerCo hasn’t just started its collaboration with QuantumScape at this point. The two companies have worked together for several years, with PowerCo conducting tests on the different prototypes of solid-state batteries that QuantumScape has developed during the past several years. That previous work is what has made it possible for the two companies to finally put pen to paper on a deal to take the battery to production.

Through this collaboration, Volkswagen Group gets to occupy the enviable position of making EVs whose batteries are breaking new ground and addressing a number of longstanding issues that have stood in the way of electric vehicles appealing to the mass market. On its part, QuantumScape gets to leverage the expertise that PowerCo has accumulated over the years in the field of manufacturing batteries. QuantumScape will also see its go-to-market capital requirements slashed by this arrangement with PowerCo.

It now remains to be seen how other automakers will respond, once VW’s new electric vehicles equipped with these batteries start reaching customers.

QuantumScape Corp. (QS), closed Wednesday's trading session at $6.46, off by 1.2232%, on 8,196,686 volume. The average volume for the last 3 months is 276,975 and the stock's 52-week low/high is $4.67/$13.86.

TerrAscend Corp. (TSNDF)

QualityStocks, CannabisNewsWire, InvestorPlace and Cabot Wealth reported earlier on TerrAscend Corp. (TSNDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The regulated cannabis sector has been facing a significant challenge lately: lab-tested products containing pesticides. More alarmingly, some cannabis samples sent for testing now contain a mixture of unknown compounds not previously identified in cannabis.

According to lab executives, these enigmatic substances emerge during the conversion of hemp-derived cannabinoids into delta-8 and delta-9 THC. The issue is made worse by the fact that testing for cannabinoids, heavy metals and mold is required in most jurisdictions, but testing for these byproducts is not. As such, their impact on customers is still unknown.

Cannabis naturally includes trace levels of delta-8 THC. However, most delta-8 products are synthesized by converting nonpsychoactive CBD, potentially leaving behind dubious byproducts.

According to chemist Susan Audino, who consults with biological and chemical laboratories, these are side reactions of the chemical process. “It is impossible to produce one compound without also producing others,” she added.

According to Josh Swider, CEO and cofounder of Infinite Chemical Analysis Labs in San Diego, up to 60 unknown chemicals are frequently present in many delta-8 products made via chemical procedures. Many of them remain unidentified. This suggests that previously undiscovered cannabis chemicals are being digested and introduced, according to Swider.

ACT Laboratories CEO and chief scientific officer, Bob Miller, pointed out that unethical methods used in THC-potency testing are partially to blame for the paucity of investigation into these unidentified chemicals. “Potency testing creates an opportunity for unethical interactions between labs and grower-processors,” Miller said. “Higher potencies benefit everyone except the consumer because they mean more money for the tests and higher sales prices.”

Miller highlighted that his lab in Michigan has observed an increase in delta-8 THC entering the market, posing a significant issue. “Producers often claim they have hemp and sell it across state lines. In reality, it’s a mix of delta-9 and delta-8 THC,” he said. The conversion process from CBD to delta-9 and delta-8 is often imprecise, resulting in a mix of various compounds, many of which remain unidentified due to the lack of required testing.

Certain molecules that arise from these intricate combinations in lab settings have the potential to be more psychotropic than delta-9 THC. “If we detect significant levels of any compound, we inform our clients,” Miller explained. “Some clients are eager to understand, while others just want us to test for the legally required cannabinoids.”

The tests carried out are chosen by the lab’s clients, the manufacturers of the products. “Manufacturers usually don’t request specific tests if regulations don’t demand them,” said Audino, who also pointed out that the majority of state regulators are lawyers enforcing laws rather than scientists.

Miller drew attention to the fact that the influx of these unidentified substances was unintentionally facilitated by the 2018 Farm Bill, which authorized industrial hemp. “There’s a federal movement to change regulations to eliminate unknown chemistry and stabilize the supply chain,” he said.

Swider criticized the cannabis-lab industry for moving away from science. “Labs have become more cookie-cutter, focusing only on mandated tests and ignoring other potential issues,” he said. Swider believes the industry needs a reset, urging states to establish stricter mandates. “Many labs prioritize profit over safety, and about 70%–80% of them probably shouldn’t be operational.”

Making the needed changes will require the concerted efforts of all stakeholders, including established cannabis entities such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF), so that only accepted compounds remain in the products that reach the market.

TerrAscend Corp. (TSNDF), closed Wednesday's trading session at $1.4, off by 2.6832%, on 216,763 volume. The average volume for the last 3 months is 17,314 and the stock's 52-week low/high is $1.07/$2.45.

LeddarTech Holdings Inc. (LDTC)

MarketBeat and FreeRealTime reported earlier on LeddarTech Holdings Inc. (LDTC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

LeddarTech(R) Holdings (NASDAQ: LDTC), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology, announced that it will be unveiling the high-performance LeddarNavigator to automotive OEMs and Tier 1s during its tour across Europe.

Antonio Polo, Sr. Vice-President of Product and Business Development at LeddarTech, stated, “The introduction of our European LeddarNavigator is a tremendous step forward for LeddarTech in the European market as it enables us to truly demonstrate the performance of our software in real time to the automotive market as we have done in North America.”

To view the full press release, visit https://ibn.fm/IXD0L

About LeddarTech

A global software company founded in 2007 and headquartered in Quebec City with additional R&D centers in Montreal and Tel Aviv, Israel, LeddarTech develops and provides comprehensive AI-based low-level sensor fusion and perception software solutions that enable the deployment of ADAS, autonomous driving (“AD”) and parking applications. LeddarTech’s automotive-grade software applies advanced AI and computer vision algorithms to generate accurate 3D models of the environment to achieve better decision making and safer navigation. This high-performance, scalable, cost-effective technology is available to OEMs and Tier 1-2 suppliers to efficiently implement automotive and off-road vehicle ADAS solutions. LeddarTech is responsible for several remote-sensing innovations, with over 160 patent applications (87 granted) that enhance ADAS, AD and parking capabilities. Better awareness around the vehicle is critical in making global mobility safer, more efficient, sustainable and affordable: this is what drives LeddarTech to seek to become the most widely adopted sensor fusion and perception software solution. For more information, visit the company’s website at www.LeddarTech.com.

LeddarTech Holdings Inc. (LDTC), closed Wednesday's trading session at $0.69, off by 4.1933%, on 18,398 volume. The average volume for the last 3 months is 213,191 and the stock's 52-week low/high is $0.6111/$11.2.

The QualityStocks Company Corner

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB) .

Lexaria, a global innovator in drug delivery platforms, has released interim results from its WEIGHT-A24-1 animal study

The study sought to explore the impact of its patented DehydraTECH technology on glucagon-like peptide-1 ("GLP-1") drugs for the potential treatment of diabetes and weight loss, representing a major global market

The first 28 days of dosing yielded positive results that Lexaria's management described as "noteworthy"

It also marked a significant milestone for the company and the first time it has used liraglutide in any of its GLP-1 studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery enhancement, just released interim results from its WEIGHT-A24-1 animal study. The study evaluated the company's patented DehydraTECH technology and its potential to address diabetes and weight loss. The first four weeks of dosing was successful, with Lexaria's management describing its findings as "noteworthy" (https://cnw.fm/nRqEL).

SuperCom Ltd. (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary Puresecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (AI) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

  • Long Battery Life (No Tag Charging Required)
  • Ultra Lightweight Form Factor
  • Next-Gen Location Tech
  • Protection of Domestic Violence Victims
  • And More

 

Cybersecurity

In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.

e-Gov

Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

SuperCom Ltd. (NASDAQ: SPCB), closed Wednesday's trading session at $4.09, up 11.4441%, on 283,420 volume. The average volume for the last 3 months is 4.144M and the stock's 52-week low/high is $0.80/$6.85.

Recent News

Correlate Energy Corp. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Energy Corp. (OTCQB: CIPI).

D-Wave Quantum Inc. (NYSE: QBTS) ("D-Wave"), a leader in quantum computing systems, software and services, will release its financial results for the second quarter of 2024 on Aug. 8, 2024, before the market opens. The financial report will cover the three and six month periods ended June 30, 2024. In addition, the company has scheduled a conference call on that same day. The call will begin at 8 a.m. ET. During the call, CEO Dr. Alan Baratz and CFO John Markovich will discuss the results and business outlook. Those wishing to access the call can dial 1-800-717-1738 (domestic) or 1-646-307-1865 (international). To view the full press release, visit https://ibn.fm/Jj2wb

Correlate Energy Corp. (OTCQB: CIPI) is a publicly-traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation.

The energy grid in the U.S. is insufficient for the booming clean energy trend, and current infrastructure is limiting green energy distribution. Constructing the needed infrastructure to address this demand imbalance will cost billions and be far too slow, positioning decentralized systems, like those on offer from Correlate, in a key position for heightened demand.

Correlate has identified several key economic drivers powering the decentralized energy trend, including:

  1. Real Cost Savings – Customer pays zero money down and gets an instant electrical price discount to current rates.
  2. Massive Project Investment Funding – The International Energy Agency estimates that over one billion dollars per day will be invested in solar energy in 2023.
  3. Consistent Long-Term Incentives – The Inflation Reduction Act is a game-changer, supercharging renewables with $1.2 trillion in tax credits for 10 years of market support.
  4. Robust Customer Demand – Wood Mackenzie expects the U.S. solar industry to nearly triple in size over the next five years.

Correlate’s team of multi-decade experts who have worked with renowned global brands are positioning the company to make the most of this opportunity while consolidating a fragmented industry. Collectively, the team has developed, financed and deployed over $2 billion in clean energy projects to date.

Three-Pronged Strategy

Correlate is leveraging a three-pronged strategy aimed at driving shareholder value:

  1. Sell – Correlate seeks to finance, develop and profitably sell localized clean energy solutions and microgrids to industrial, commercial and residential customers.
  2. Retain – Correlate plans to retain ownership of some of these energy systems and thereby realize ongoing, reliable cash flow.
  3. Acquire – Correlate seeks to acquire proven renewable energy companies in order to exponentially grow earnings per share for investors.

This strategy is enhanced by current investment trends. Clean energy earnings are being sought after by investors. In Q4 2022, the median EBITDA multiple for green energy companies was 12.3x, according to Finerva.

Market Outlook

Over the next decade and beyond, renewable energy growth is expected to come primarily via decentralized systems like those offered by Correlate.
The Inflation Reduction Act enacted in late August 2022 is likewise expected to drive growth for the company by providing new tax incentives that reduce costs for clients and/or elevate returns to investors.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings, yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which are very different from traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue, known as the ‘split incentive’, unlocking the majority of the addressable market.

A key portion of Correlate’s strategy relates to consolidation of what has been a fragmented industry. By uncovering opportunities to improve efficiencies through strategic M&A activities, the company intends to enhance profitability throughout its operations.

Management Team

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

Dave Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jed Freedlander is the company’s Chief Development Officer. He has a background in infrastructure development and investment and a strong legal, commercial and finance acumen. Mr. Freedlander has a proven track record in leading complex public-private partnership (P3) and energy transactions and is instrumental in driving Correlate’s strategic development initiatives.

Roger Baum is Executive VP Operations at Correlate. With over 20 years of experience at Core Construction, he brings to the company a wealth of knowledge and a strong track record in delivering successful commercial construction projects.

Jason Loyet is Director of Solar Energy for Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Correlate Energy Corp. (OTCQB: CIPI), closed Wednesday's trading session at $1, up 4.712%, on 2,424,941 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $6.85/$.

Recent News

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

Last week, the European Union introduced a law focused on increasing the sustainability of products in the market. The comprehensive regulation, called Ecodesign for Sustainable Products Regulation, complements the Ecodesign Directive, focusing on enhancing environmental sustainability, energy performance and circularity while covering almost all physical goods. In a statement, an EU spokesperson explained that environmental sustainability wasn't just about energy efficiency but also ensured that the lifecycle of a product was considered during its design. These Ecodesign regulations merge environmental considerations into every stage of product development, an approach that is critical in decreasing resource and energy consumption in a world that demands sustainable and efficient products. In the past, the European Union's rules on ecodesign have produced significant benefits. In 2021 alone, these rules decreased the annual consumption of energy of covered products by 10% while also saving consumers in this trading bloc €120 billion ($154.4 billion) in energy costs. The new regulation underlines the bloc's commitment to sustainability and its intention to deliver long-term benefits to consumers and businesses as well as the environment. The step taken by the EU could eventually see different iterations of the regulation adopted in other jurisdictions, including the markets in which companies such as First tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) operate.

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Wednesday's trading session at $0.091, up 5.2023%, on 400 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.047785/$0.1028.

Recent News

Horizon Fintex | Upstream

The QualityStocks Daily Newsletter would like to spotlight Horizon Fintex | Upstream

MedCana has identified Colombia's Antioquia Valley as a perfect location to begin its initial rollout of technology and production

The company is working with five subsidiaries in the area, each of which has three licenses to produce, process and export cannabis

Equally important to MedCana is working closely with the people of the Antioquia Valley and maintaining its commitments to its investors

Cannabis legalization is not exclusive to North America. So far, more than 40 countries have legalized cannabis fully or partially for medical and/or adult use (https://cnw.fm/H7Jbq). With its focus on the global horizon, Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) has a vision of building its partner companies into one of the world's most advanced cannabinoid production and processing organizations.

Horizon Fintex is a software business specializing in compliant securities solutions. The company aims to facilitate the future of capital markets by leveraging the regulatory experience of Wall Street bankers and the proven track record of technology veterans to bring focus to compliance, efficiency, security and transparency.

Horizon’s flagship product is the revolutionary trading app ‘Upstream’, a MERJ Exchange Market, and the first regulated market powered by a blockchain to offer both digital securities and NFT trading. Upstream traders experience T+0 settlement, best bids and offers displayed on a transparent public orderbook that prevents predatory market practices – all from a user-friendly trading app.

Products

Horizon Fintex offers a full suite of end-to-end blockchain-enhanced software solutions to create a seamless experience for both issuers and investors. Its product suite includes:

  • Securitization & IssuanceETSware is an end-to-end Electronic Trading System streamlining capital raising from primary issuance through compliant secondary trading.
  • KYC Compliance OnboardingKYCware is a white label Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance software solution offering best-in-class cryptographic security to compliantly onboard and verify user identity through a smartphone application.
  • AML Screening SoftwareAMLCop offers advanced Anti-Money Laundering (AML) software to streamline the verification of user details against a proprietary database of global sanctions, politically exposed persons (PEPs) and watchlists.
  • Cap. Table Management ToolsCustodyWare equips registered U.S. transfer agents with next-generation cap. table management software to manage securities on behalf of their clients pursuant to an SEC-registered or exempt securities offering.
  • Exchange & Trading App TechnologyOpen Order Book offers Ethereum blockchain securities exchange software to power the next generation of trading venues for digital assets.

Upstream – The Horizon-Powered Trading App

Upstream is a joint venture with MERJ Exchange (merj.exchange), an affiliate of the World Federation of Exchanges.

Upstream aims to be the premiere global trading hub offering issuers around the world exposure to a digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD (fiat) to increase liquidity and enhance price discovery; while also offering investors access to dual-listed companies, IPOs, crowdfunded companies, U.S. & Int’l. equities, digital coupons and NFTs directly from a user-friendly trading app.

Upstream aims to unlock liquidity for investors of all levels while offering industry-leading levels of transparency, accessibility and investor protections enforced using Ethereum blockchain technology.

Management Team

Brian Collins is the CEO of Horizon Fintex. He founded the company in 2010. From 1999-2010, Mr. Collins was CEO of Abbey Technology in Switzerland, specializing in the design of trading software for Swiss banks. Prior to this, he worked for Credit Suisse in Zürich, designing and building proprietary equity trading solutions. Mr. Collins graduated in 1990 with a BS in Computer Systems from the University of Limerick, Ireland.

Mark Elenowitz is the company’s President. He is a Wall Street veteran with over 29 years of experience. Mr. Elenowitz was the co-founder of a U.S. broker dealer and is Managing Director of two U.S. broker dealers, responsible for advising clients on compliance, capital structure and capital market navigation. He was responsible for leading the first successful Reg A+ IPO of a company to list on the NYSE and others which listed directly onto Nasdaq. He is a noted speaker at Small Cap and Reg A events, including the SEC Small Business Forum, and has been profiled in BusinessWeek and CNBC, as well as several other publications. Mr. Elenowitz is a graduate of the University of Maryland School of Business and Management with a BS in Finance and holds Series 24, 62, 63, 79, 82 and 99 licenses.

Dr. Andrew Le Gear is the CTO of Horizon Fintex. Prior to joining the company in 2013, he worked as a software engineer with Dell Inc. (2012-2013) and Lehman Brothers and Nomura Plc. (2007-2012). Dr. Le Gear was a co-founder of Juneberi Ltd., a research-driven software tech start-up (2004-2007). He graduated in 2006 with a Ph.D. in Computer Science from the University of Limerick, Ireland.

Peter Hall is the company’s CIO. Prior to joining Horizon Fintex in 2011, he worked at Microsoft (2008-2011), Atos Origin (2004-2008) and AIT Group Plc. (1998-2002). Mr. Hall has held CISSP certification since 2010. He graduated from the University of Sheffield, UK in 1995 and earned an MS from the University College London in 2006.

Mike Boswell is the CFO of Horizon Fintex. A Wall Street veteran, he co-founded a U.S. broker dealer and served as Chief Compliance Officer. Mr. Boswell was also Managing Director of TriPoint Capital Advisors, a merchant banking and financial consulting company, and CFO of Mission Solutions Group, a privately held defense sector firm. He earned an MBA from John Hopkins University and a BS in Mechanical Engineering from the University of Maryland. Mr. Boswell holds Series 24, 62, 63, 79, 82 and 99 licenses.

Recent News

chart

Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Annovis Bio Inc. (NYSE: ANVS).

Investors have been flocking to gold in the past few months, many focused on capitalizing on the metal's uptick in price. Earlier this year, the metal's price started going higher before reaching its first record of the year in March. By mid-July, gold had surpassed many highs to reach $2,472 an ounce, its newest record. Since then, the price of the precious metal has dropped to $2,371.45 an ounce, representing a drop of nearly 4%. With the Fed set to make a new announcement and the rate of inflation cooling, the price of gold is expected to go down, at least over the short-term. While this isn't necessarily a bad thing, investors who are skeptical can consider the following moves in this current climate. A gold IRA allows investors to physically hold precious metals such as gold as part of one's retirement portfolio, combining tax advantages with the benefits of owning gold. This is particularly beneficial in the long-term as investors enjoy tax-free or tax-deferred growth. This strategy may benefit investors seeking to diversify savings from their retirement while protecting their portfolios from economic instability or currency devaluation. For those looking to invest in gold stocks, there are almost unlimited alternatives from which to choose, with twists to each possible investment. For example, companies such as GEMXX Corp. (OTC: GEMZ) not only extract gold but also make finished products, including jewelry, from this precious metal.

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach aims to treat memory loss and dementia associated with AD and body and brain dysfunction associated with PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, Buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, Buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a -3.3 point improvement compared to -0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating Buntanetap’s mechanism of action.

Similarly, in the Phase III study of Buntanetap in patients with early Parkinson’s disease, significant advancements were observed. Topline data results are anticipated in June 2024. Preliminary findings indicate promising results in improving cognitive and motor function, underscoring Buntanetap’s potential as a transformative therapy for Parkinson’s disease.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050 (Alzheimer’s Association) (Republican Policy Committee). Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease (SingleCare).

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

  • Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
  • Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
  • Groundbreaking Clinical Insights: Preliminary results from Phase II studies indicate significant improvements in motor functions and speed in patients with Parkinson’s Disease (PD).
  • Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate Buntanetap’s disease-modifying potential.
  • Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

Maria L. Maccecchini, Ph.D., Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.

Cheng Fang, Ph.D., Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.

Michael Christie, Ph.D., VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.

Melissa Gaines, Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.

Learn more about the Annovis Bio team on LinkedIn.

Annovis Bio Inc. (NYSE: ANVS), closed Wednesday's trading session at $0.0211, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0172/$0.19.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations, is spotlighted in the latest episode from The GotStock Podcast, which is released by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. SenesTech president and CEO Joel Fruendt is the featured guest on the most recent episode, which is hosted by IBN's Carmel Fisher. During the interview, Fruendt provides an overview of the company and its business model, noting that SenesTech's mission is to help manage animal-pest populations, particularly rodents, through fertility control. He explained that the company's proprietary ContraPest(R) is based on a patented, proven technology that reduces or eliminates fertility in both females and males. Part of IBN's commitment to provide specialized content distribution via widespread syndication channels, The GotStocks Podcast puts the small-cap sector in the limelight with in-depth interviews featuring executives in key companies. "Right now, we have labels for rats and mice, and we attack the problem at its root cause – reproduction," said SenesTech president and CEO Joel Fruendt. "I'll start out with this fact that usually leaves people with their jaws dropping: two rats, in one year, can become 15,000. That is really the basis for our product. You cannot poison, trap or drown rats fast enough without addressing the reproductive rate, and that is really why our product is in the news a lot right now and why we're getting such success out in the marketplace."

To view the episode, visit https://ibn.fm/8EupT

To view the full press release, visit https://ibn.fm/ZtVGl

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Wednesday's trading session at $4.605, off by 4.2102%, on 11,974 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.00/$112.872.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, is participating as an Anchor Organization and panelist at the 2024 Southeastern United States - Canadian Provinces ("SEUS-CP") Business Forum. The 2024 SEUS-CP is set to take place August 4-6 in Biloxi, Mississippi; Mississippi is home to Mullen's commercial EV manufacturing. Mullen is a confirmed Anchor Organization at the event alongside other companies. According to the announcement, this year's business forum focuses on Advanced Manufacturing (Aerospace and Electric Vehicle Technologies and Components) and the Blue Economy (Shipbuilding, UAVs, Smart Ports Energy, Innovative Materials, Innovative Technologies & Data Analytics, Fisheries & Aquaculture). The SEUS-CP alliance was established in 2007 to formally advance a common interest in enhancing economic ties between the two regions and is a strategic trade and investment-focused partnership between six southeastern states and six provinces. The alliance meets every year to present clear B2B opportunities for enhanced commercial exchanges, two-way trade and investment, and knowledge sharing between and among member states and provinces. "Mullen has a deep commitment to the Southeast U.S. region with our commercial EV manufacturing located in Tunica, Mississippi, and our participation as an Anchor Organization in this year's SEUS-CP forum underscores our focus on Mississippi," commented David Michery, CEO and chairman of Mullen Automotive. "We look forward to showcasing our innovative lineup of commercial EVs and connecting with industry leaders, potential customers, and strategic partners."

To view the full press release, visit https://ibn.fm/vrFna

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $1.16, off by 13.7546%, on 5,740,935 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.09/$155.70.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

Cases of neurodevelopmental disorders have increased globally in the last couple of years, with countries such as Italy observing a significant increase in cases of autism, noting that the disorder is more than four times higher in males than females. Autism spectrum disorder affects how individuals interact with others, as well as how they behave, learn and communicate. This disorder is said to have multifactorial origins, with recognized environmental and genetic triggers. Researchers posit that the period between fetal life through early childhood is the most vulnerable time for neurodevelopmental disorders. They argue that during this period, exposure to neurotoxic chemicals, be it in minimal or high doses that have no adverse effects in grownups, may get in the way of ongoing neurological development, causing permanent damage to the brain. In their report, the researchers explained that increasing scientific evidence had linked autism to environmental exposures. They added that the steel plant's emissions included heavy metals and endocrine disruptors, which has been recognized as playing a role in autism development. The researchers' findings add to data on how heavy industrial pollution is a challenge for children and needs to be treated as a public-health priority. The insights from this study could give public-health experts suggestions on which areas need more consignments of the ASD treatments developed by entities such as PaxMedica Inc. (OTC: PXMD), given the resource constraints authorities face and the need to optimize value from what is available as preventive efforts are also implemented.

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Wednesday's trading session at $0.24, off by 1.9608%, on 3,295 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.20/$12.24.

Recent News

Torr Metals Inc. (TSX.V: TMET)

The QualityStocks Daily Newsletter would like to spotlightFathom Torr Metals Inc. (TSX.V: TMET) .

America's power grid will have to undergo significant changes before it is ready to effectively handle the massive influx of renewables. Electrification has emerged as one of the most critical weapons against climate change because it will allow for the use of renewables to power the country's energy needs. However, even though the United States has made admirable progress in the deployment of renewable energy infrastructure, connecting renewables to the grid and getting it to customers has proved to be a significant challenge. An expert team with members from Florida State University, Ohio State University and the National Renewable Energy Laboratory (NREL) is now working to develop a novel type of grid technology that can give regulators much better control over the flow and direction of electricity. The four-year project has culminated in the development of a device called a "back-to-back medium-voltage converter" that can significantly improve the grid operators' control of electricity flow. For instance, a sudden burst of solar energy during a particularly sunny afternoon could lead to grid faults that can snowball and result in outages or overload power lines. The new prototype could be used to develop new grid technologies to prevent such poor outcomes and allow the U.S. to integrate the energy generated from renewables into its grid. As these efforts to accelerate adding renewables to grids gain momentum, other contributors to the energy switch, including critical minerals extraction companies such as Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF), are also ramping up their operations so that the demand for these metals can be adequately addressed in the coming years and decades.

Torr Metals Inc. (TSX.V: TMET) operates as a mineral exploration company focusing on the identification, acquisition, and advancement of mineral properties. With full 100% ownership of over 1,000 square kilometers of gold and copper projects strategically positioned in premier low-cost mining jurisdictions, Torr is poised for substantial returns across various promising regions.

The company’s extensive portfolio encompasses multiple district-scale projects, including the Filion Gold Project in northern Ontario, the Kolos Copper-Gold Project in south-central British Columbia, and the Latham Copper-Gold Project in northern British Columbia. These projects are all located in prolific mining regions with paved highway access, robust support infrastructure, and favorable geological conditions offering significant potential for new discoveries.

Headquartered in Vancouver, British Columbia, Torr Metals is ideally situated to leverage its expertise and resources for continued exploration and growth.

Projects

Kolos Copper-Gold Project

Situated within British Columbia’s prime copper-producing belt, the 140-square-kilometer Kolos Copper-Gold Project exhibits Nicola Belt geology similar to notable porphyry mines, including Copper Mountain and Highland Valley, respectively situated 106 kilometers to the south and 30 kilometers to the northwest.

With field operations based in the nearby city of Merritt and year-round access provided via Highway 5, the Kolos Project showcases substantial discovery upside potential with five defined large-scale copper-gold-molybdenum anomalies untested by drilling.

Torr Metals’ primary focus lies in unlocking the potential for major new discoveries at the Kolos Copper-Gold Project, with recent surface geochemical results marking a significant milestone positioning the company as a new key player in the region.

Filion Gold Project

The 261-square-kilometer Filion Project is situated within a largely unexplored greenstone belt where gold was initially discovered in the 1930s. With a comparable geological setting to regional orogenic gold deposits and multiple newly identified and undrilled gold trends in surficial geochemistry, the Filion Project holds significant district-scale exploration promise.

The Filion Project benefits from unparalleled infrastructure access, with direct drive-on access from the Trans-Canada Highway, as well as a regional railway and power grid four kilometers to the south. Additionally, the nearby town of Kapuskasing, with a population of 8,300, provides essential support services.

This strategic positioning ensures the Filion Project’s viability for cost-effective, year-round operations in an area poised for untapped discovery potential.

Latham Copper-Gold Project

Situated in British Columbia’s renowned Golden Triangle, the Latham Project spans a vast 689-square-kilometer district, offering immense potential for multiple major discoveries. Accessible year-round via Highway 37, just 20 kilometers south of the town of Dease Lake, the site is strategically located amidst established mining infrastructure, including the active Red Chris mine to the southeast and upcoming major porphyry projects at Schaft Creek and Galore Creek along-trend to the southwest.

Highlighted by the Gnat Pass copper-gold porphyry deposit dating back to the 1960s, the Latham Project presents a compelling opportunity for significant expansion and potential discovery. A non-compliant indicated resource at the Gnat Pass deposit includes 33 million tonnes at 0.39% copper, open beyond 200 meters vertical depth, alongside six drill-ready kilometer-scale copper-gold exploration targets.

Moreover, the Latham Project’s appeal corresponds to the region being an attractive destination for major asset acquisitions and takeovers. Recent transactions within a 40-kilometer radius include Newmont’s 2021 acquisition of the Saddle North copper-gold porphyry deposit for $311 million and Newcrest’s investment in the Red Chris copper-gold porphyry deposit in 2019 for $804 million, underscoring industry acknowledgment of the region’s potential.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 that the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

Likewise, a report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Malcolm Dorsey, P.Geo., is President, CEO and Director of Torr Metals. He brings over a decade of expertise as a seasoned exploration geologist and project developer, having been pivotal in driving the success of numerous diverse projects across North, Central, and South America. His comprehensive background spans early-stage exploration through to resource development and project acquisitions. His academic credentials include an M.Sc. in Geology and Geophysics from the University of Calgary, where his research characterized the district-scale structural influences affecting copper and gold mineralizing events in western British Columbia. Prior to his current role, he served as Senior Geologist for Benchmark Metals, where his contributions were instrumental in advancing the company’s gold equivalent resource from approximately 80,000 ounces to a maiden resource estimate of 2.92 million ounces.

John Williamson, P. Geol., is Chairman and Director of Torr Metals. He is a mining executive and investor with more than 30 years of experience as a founder, promoter and leader in the formation, financing and operation of private and public companies with exploration and mining interests worldwide. On more than one occasion his team’s efforts have been recognized for excellence by being named to the TSX Venture 50. He holds a B.Sc. in Geology and is a registered Professional Geologist (P.Geol.) with the Association of Professional Engineers and Geoscientists (APEGA) and the Geological Association of Canada.

Torr Metals Inc. (TSX.V: TMET), closed Wednesday's trading session at $0.031, off by 23.3622%, on 39,178 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.03/$0.35.

Recent News

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF)

The QualityStocks Daily Newsletter would like to spotlight Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF).

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF), along with its consolidated subsidiaries, is a Canadian oil and gas exploration and production company with operations primarily focused in the Republic of Türkiye.

Headquartered in Canada, the company owns 49% of the SASB natural gas field, which is producing critical domestic supply of natural gas during Europe’s ongoing energy shortages. It also holds a 19.6% (except three wells with 9.8%) ownership interest in the Cendere Oil Field and has a farm-in agreement to earn 50% interest in three oil exploration blocks in southeast Türkiye called Cudi-Gabar.

Trillion Energy utilizes state-of-the-art technology and ingenious practices to produce and distribute oil and natural gas while still maintaining a commitment to sustainable and responsible operations. Whether through the development of new projects or optimizing existing assets, the company continues to seek new and innovative ways to drive growth and value for its stakeholders.

Headquartered in Vancouver, British Columbia, Trillion Energy is led by seasoned professionals who collectively boast over a century of energy exploration and development experience.

Projects

SASB Gas Field

The SASB Gas Field is producing and delivering critical domestic supplies of natural gas as energy shortages grip Europe due to Russia’s invasion of Ukraine.

Located in the southwestern Black Sea, the SASB gas field consists of numerous conventional natural gas pools located in shallow water. The fields have produced over 43 billion cubic feet (BCF) since initial development in 2007 and continue to provide much needed energy to Türkiye and the EU. Total infrastructure to date, including production platforms, pipelines, initial wells and gas processing plant, cost in excess of $600 million.

Trillion Energy is redeveloping the field with a strategic planned program of approximately 17 wells which commenced in 2022. Phase B of the program, targeted for 2024/25, consists of the re-entry of five legacy wells to drill sidetrack development wells and one exploration stratigraphic well.

Cendere Oil Field

Trillion Energy’s Cendere oil field is a long-term, low decline, stable oil production field located in Türkiye. The company has a 19.6% interest in the field, except for three wells in which its interest is 9.8%.

Cash flow after operating costs from the field is $120,000 to $140,000 per month, with average current production netting the company 110-120 barrels of oil per day. Estimated remaining Cendere oil reserves total 1.5 million barrels (0.277 million barrels net Trillion Energy).

The gross value of Trillion Energy’s interest is estimated at $13.85 million (NPV10).

Cudi-Gabar

Trillion Energy’s 10-well oil exploration drilling program is occurring on three prospective oil blocks located in the prolific Cudi-Gabar oil province in southeast Türkiye. The total area of the three blocks is 374,325 acres.

Trillion Energy’s potential 50% working and revenue interest in the blocks is earned by paying 100% of the work program costs. The company will operate the exploration program.
During 2023/24, Trillion Energy will shoot 351 kilometers of 2D seismic (150 km already shot on the eastern block) and drill four wells. The remaining six wells will be paid 50% by Trillion and 50% by the company’s partner. The oil blocks are surrounded by more than 10 major oil discoveries, half of which are recent.

Market Opportunity

A January 2024 report by Emergen Research, a market research and consulting company, estimated the global natural gas market at $310.5 trillion in 2022 and projected the market will be worth $443.8 trillion by 2032, achieving a CAGR of 3.7% during the forecast period. Increasing global economic activity and rising electricity consumption are key factors driving revenue growth of the market, according to the report.

Trillion Energy reports strong demand for natural gas in Türkiye, which is the seventh-largest natural gas consuming country in the world. Türkiye currently imports 98% of the natural gas it consumes, with about 60% of those imports coming from Iran and Russia.

Management Team

Dr. Arthur Halleran is CEO and Director of Trillion Energy. He has a Ph.D. in Geology from the University of Calgary and 44 years of petroleum exploration and development experience. His international experience includes work in Canada, Colombia, Egypt, India, Guinea, Sierra Leone, Sudan, Suriname, Chile, Brazil, Bulgaria, Türkiye, Pakistan, Peru, Tunisia, Trinidad Tobago, Argentina, Ecuador and Guyana. Dr. Halleran has worked for Petro-Canada, Chevron, Rally Energy and United Hydrocarbon International Corp. In 2007, he founded Canacol Energy Ltd., now the largest natural gas producer in Colombia.

Al Thorsen is COO of Trillion Energy. He is responsible for production operations of the SASB gas field, as well as future drilling activities in Türkiye and abroad. Highlights of his career include Valeura Energy Inc. as operations manager in Türkiye; Journey Energy, leading a production team; Rio Alto Exploration as country manager and production manager; Zargon Oil and Gas as VP of Operations; Orleans Energy as VP of Operations; and Central Petroleum as COO. He holds a Bachelor of Science in Petroleum Engineering from Montana College of Mineral Science & Technology.

Trillion Energy International Inc. (OTCQB: TRLEF), closed Wednesday's trading session at $2.61, up 10.1266%, on 112,611 volume. The average volume for the last 3 months is 119,270 and the stock's 52-week low/high is $1.06/$3.3893.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Wednesday's trading session at $1.4399, up 7.4552%, on 63,580 volume. The average volume for the last 3 months is 194,867 and the stock's 52-week low/high is $1.21/$2.50.

Recent News

Bebuzee Inc. (OTC: BBUZ)

The QualityStocks Daily Newsletter would like to spotlightFathom Bebuzee Inc. (OTC: BBUZ) .

Bebuzee Inc. (OTC: BBUZ), formerly Engage Mobility Inc., is a social platform and streaming service focused on development and deployment of America’s first superapp. The superapp will allow members to watch a wide variety of content, such as movies, series, documentaries and talk shows, on any internet-connected device.

Bebuzee’s technology scans the world’s news, features and information-flow to give its dedicated readers the best of the internet in one place – a one-stop platform for breaking news, interesting and important blogs, videos and photos.

The core features of the superapp include video streaming; photo sharing; Bebuzee Messaging service, which allows users to send text and voice messages and make voice and video calls; Shortbuz, used to make a variety of short-form entertaining videos; Blogbuz, a resource for people without time to scavenge the internet and other sources for news and information; Properbuz global real estate search; global tradesmen search; location reviews of neighborhoods, cities and even regions to help others find their ideal rental or real estate purchase; ShoppingBuz, a unique technology-driven e-commerce platform which gives merchants incredible tools to sell their products; Bebuzee Pay, a mobile payment and digital wallet service that allows users to make mobile payments and online transactions; TravelBuz, an online travel booking service; EventBuz, a ticket exchange and resale platform; and FlightBuz, a flight search engine.

The company is headquartered in Miami.

Introducing the Superapp to Western Markets

A superapp is a mobile phone app that offers a wide range of services within a single platform. This technology allows users to access various services without downloading and switching between multiple apps.

While superapps are popular in many parts of the world, including Latin America, Africa, the Middle East, Asia and Russia, they have achieved little adoption in Western markets. Perhaps the most widely known superapp is WeChat, which is estimated to have as many as 1.24 billion users, mostly in China.

Bebuzee aims to be the first developer to introduce and grow to widespread popularity a superapp in the U.S. and Europe. It took a strong step toward achieving this goal during the COVID-19 pandemic, when Bebuzee’s user base surged by 78% with over 42 million new users.

Whereas most social platforms are generic and only local postings make them somewhat relevant to local communities, Bebuzee has localized its platform for most countries by providing local content, entertainment and information that is frequently updated and refreshed.

The company says the average age of its superapp users is 39, with female users making up 62.8% of its user base. Its monetization strategy includes sales of video advertising, sponsored posts, banner ads and premium listings, as well as promotion of featured brands and property listings.

Market Opportunity

A report from Allied Market Research, a global market research, consulting and advisory firm, estimated that the worldwide superapps market was valued at $58.6 billion in 2022. The report projects the market to expand to $722.4 billion by 2032, growing at a CAGR of 28.9% for the forecast period.

The report identifies a few of the most popular superapps as Rappi in Latin America, Snapp in Iran, Line in Japan and Yandex Go in Russia and Kazakhstan.

Increasing adoption of mobile services and growing advancements in digital technologies are driving the growth of this market. In addition, a rise in government support for promoting the use of superapps is lending to expansion, according to the report.

Integration of blockchain technology in superapps is likewise anticipated to provide numerous opportunities for the expansion of the market during the forecast period, the report states.

Management Team

Joseph Onyero is Founder and CEO of Bebuzee. He has a background of managing multiple products from ideation to market launch and profitable monetization and has been building commercial web presences since 2005. He has worked as a Chief Marketing Officer and in business development. He previously owned and operated a travel and tourism company. He began in 2005 working on the concept and features that have evolved into the Bebuzee suite. He has grown Bebuzee from a living room start-up into a U.S. publicly traded company.

Claudia S. Spagnuolo is Chief Operating Officer at Bebuzee. She began with the company in 2014 as a user experience manager before being promoted to CMO in 2017. She previously worked as an assistant marketing director at the National Secretariat of the union CISL in Italy. Prior to that, she also worked as a researcher at the Complutense University of Madrid on issues of corporate management. She speaks three languages and holds a bachelor’s in political science and a master’s in administration from the University of Perugia in Italy.

Bebuzee Inc. (OTC: BBUZ), closed Wednesday's trading session at $0.225, up 7.1429%, on 3,421,995 volume. The average volume for the last 3 months is 4.829M and the stock's 52-week low/high is $0.1957/$14.00.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.